Calidi Biotherapeutics Inc (CLDI) concluded trading on Wednesday at a closing price of $3.38, with 23.26 million shares of worth about $78.61 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 44.69% during that period and on November 13, 2024 the price saw a gain of about 60.19%. Currently the company’s common shares owned by public are about 11.68M shares, out of which, 9.73M shares are available for trading.
Stock saw a price change of 133.10% in past 5 days and over the past one month there was a price change of 221.90%. Year-to-date (YTD), CLDI shares are showing a performance of -77.62% which decreased to -84.28% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.73 but also hit the highest price of $26.30 during that period. The average intraday trading volume for Calidi Biotherapeutics Inc shares is 555.07K. The stock is currently trading 142.38% above its 20-day simple moving average (SMA20), while that difference is up 174.84% for SMA50 and it goes to 16.84% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Calidi Biotherapeutics Inc (AMEX: CLDI) currently have 11.68M outstanding shares and institutions hold larger chunk of about 10.25% of that.
The stock has a current market capitalization of $39.47M and its 3Y-monthly beta is at 0.97. It has posted earnings per share of -$7.16 in the same period. It has Quick Ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLDI, volatility over the week remained 31.35% while standing at 24.08% over the month.
Stock’s fiscal year EPS is expected to rise by 77.06% while it is estimated to increase by 77.15% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on November 22, 2023 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by Robert W. Baird stated Calidi Biotherapeutics Inc (CLDI) stock as an Outperform in their note to investors on October 09, 2023, suggesting a price target of $9 for the stock.
